Reference
Eli Lilly. Lilly's CYRAMZA(Rm) (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma. Media Release : 13 May 2019. Available from: URL: http://www.lilly.com
Rights and permissions
About this article
Cite this article
Boxed warning removed from US labelling for ramucirumab. Reactions Weekly 1754, 1 (2019). https://doi.org/10.1007/s40278-019-62234-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-62234-3